CPTAC Partners with University of Victoria on Targeted Proteomic Assays | GenomeWeb

NEW YORK (GenomeWeb) – The National Cancer Institute's Clinical Proteomic Tumor Analysis Consortium (CPTAC) is partnering with the University of Victoria Genome British Columbia Proteomics Centre to develop targeted proteomic assays.

Researchers led by Christoph Borchers, director of the Proteomics Centre, will upload some 2,000 multiple reaction monitoring mass spec assays to the CPTAC Assay Portal. Borchers and his colleagues will be the first non-CPTAC researchers to upload targeted mass spec assays to the portal.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: RNA-seq, ChIP-seq to determine metformin response; array-based approach to detect protozoa in blood; and more.

Fast Company takes a look at startups in the nutrigenomic space that aim to offer personalized diet advice.

In a glamorous event, the Breakthrough Foundation gave out more than $25 million in prizes to researchers.

Immunotherapy might treat cancer, but it also appears to come with a risk of a number of side effects, the New York Times reports.